CBM-588 is under clinical development by Miyarisan Pharmaceutical and currently in Phase I for Metastatic Renal Cell Carcinoma. According to GlobalData, Phase I drugs for Metastatic Renal Cell Carcinoma have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CBM-588’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CBM-588 overview
CBM-588 is under development for the treatment of allogenic hematopoietic stem cell transplantation and metastatic renal cell carcinoma. The drug candidate is administered through the oral route. CBM-588 consists of single strain Clostridium butyricum. The drug candidate was also under development for the treatment of Escherichia coli infections, non-alcoholic fatty liver disease, inflammatory bowel diseases such as ulcerative colitis, bladder cancer and antibiotic-associated diarrhea.
Miyarisan Pharmaceutical overview
Miyarisan Pharmaceutical manufactures, processes drugs related to human and animals. The company is headquartered in Tokyo, Japan.
For a complete picture of CBM-588’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
